   KT-621: BREADTH Phase 2b Trial
   Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Dose-ranging
                                   Design
                                   • Randomized, double-blind,
                                     placebo-controlled
                                                                           Key Trial Aim
                                   • ~264 patients
                                   • Daily dose for 12-weeks               Establish clinical activity and
                                                                           safety in asthma to select Phase 3
     Adult, Moderate to            Dosing                                  dose to support registrational
 Severe Eosinophilic Asthma        • Three KT-621 doses + one placebo      studies in multiple respiratory
          Patients                   (1:1:1:1)                             indications
                                   Endpoints
     Baseline entry criteria:
                                   • Primary endpoint: Percent change
 Blood eosinophils ≥ 300 cell/uL     from baseline in pre-bronchodilator
                                                                           Status update:
        FeNO ≥ 25 ppb                FEV1 at week 12                       Initiated January 2026;
Pre-bronchodilator FEV1 40-80%
      of predicted normal
                                   • Secondary endpoints include:          Data expected
                                      • Change from baseline in ACQ-5,     late-2027
                                        AQLQ



                                                                                                           20
